Table 5 ACR response to infliximab according to genetic markers.
Marker | ACR ⩾20 (n) | ACR <20 (n) | OR | χ2 | p Value |
---|---|---|---|---|---|
SE −/− | 37 | 20 | 1 | NS | |
SE +/− | 61 | 30 | 1.1 | 0.07 | NS |
SE +/+ | 33 | 17 | 1 | 0.01 | NS |
IL1B (+3954) | |||||
C/C | 82 | 33 | 1 | ||
C/T and T/T | 49 | 34 | 0.58 | 3.24 | NS |
IL1‐RN (+2018) | |||||
T/T | 74 | 34 | 1 | ||
T/C or C/C | 57 | 33 | 0.79 | 0.59 | 0.06 |
TNFA (−238) | |||||
G/G | 127 | 62 | 1 | ||
G/A or A/A | 4 | 5 | 0.39 | 1.99 | NS |
TNFA (−308) | |||||
G/G | 99 | 48 | 1 | ||
G/A or A/A | 32 | 19 | 0.82 | 0.36 | NS |
ACR, American College of Rheumatology.